Parkman Healthcare Partners’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.88M | Sell |
599,610
-616,019
| -51% | -$5.01M | 0.56% | 61 |
|
|
2025
Q1 | $9.54M | Sell |
1,215,629
-58,160
| -5% | -$457K | 1.13% | 32 |
|
|
2024
Q4 | $19M | Buy |
1,273,789
+248,035
| +24% | +$3.69M | 2.53% | 13 |
|
|
2024
Q3 | $15.7M | Buy |
1,025,754
+610,219
| +147% | +$9.33M | 2% | 14 |
|
|
2024
Q2 | $6.33M | Buy |
415,535
+155,615
| +60% | +$2.37M | 0.85% | 41 |
|
|
2024
Q1 | $4.91M | Buy |
259,920
+12,256
| +5% | +$231K | 0.6% | 53 |
|
|
2023
Q4 | $4.73M | Buy |
247,664
+42,555
| +21% | +$813K | 0.67% | 48 |
|
|
2023
Q3 | $3.68M | Buy |
205,109
+85,060
| +71% | +$1.53M | 0.67% | 43 |
|
|
2023
Q2 | $2.44M | Buy |
120,049
+17,062
| +17% | +$347K | 0.42% | 67 |
|
|
2023
Q1 | $1.88M | Buy |
102,987
+15,527
| +18% | +$283K | 0.41% | 59 |
|
|
2022
Q4 | $1.81M | Sell |
87,460
-50,434
| -37% | -$1.04M | 0.48% | 59 |
|
|
2022
Q3 | $3.61M | Sell |
137,894
-33,320
| -19% | -$872K | 1.03% | 36 |
|
|
2022
Q2 | $4.34M | Buy |
171,214
+3,893
| +2% | +$98.7K | 1.6% | 22 |
|
|
2022
Q1 | $5.28M | Buy |
167,321
+50,222
| +43% | +$1.59M | 1.55% | 24 |
|
|
2021
Q4 | $4.74M | Sell |
117,099
-119,538
| -51% | -$4.84M | 1.05% | 29 |
|
|
2021
Q3 | $8.25M | Sell |
236,637
-10,000
| -4% | -$349K | 2.09% | 17 |
|
|
2021
Q2 | $6.77M | Sell |
246,637
-69,245
| -22% | -$1.9M | 1.48% | 23 |
|
|
2021
Q1 | $8.87M | Buy |
315,882
+84,124
| +36% | +$2.36M | 2.06% | 13 |
|
|
2020
Q4 | $6.02M | Sell |
231,758
-3,280
| -1% | -$85.1K | 1.54% | 25 |
|
|
2020
Q3 | $4.03M | Buy |
235,038
+75,038
| +47% | +$1.29M | 1.07% | 39 |
|
|
2020
Q2 | $3.96M | Buy |
+160,000
| New | +$3.96M | 1.12% | 33 |
|